Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
| Autor: | Vicente Vicente, Elisa Garcia-Garre, Maria Angeles Vicente Conesa, Teresa Garcia Garcia, Francisco Ayala de la Peña, Elena García-Martínez, Ginés Luengo Gil, Enrique Gonzalez-Billalabeitia, Asunción Chaves Benito |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Oncology
Adult medicine.medical_specialty CD3 Complex medicine.medical_treatment CD8 Antigens Antigens Differentiation Myelomonocytic Antineoplastic Agents Breast Neoplasms Antibodies Monoclonal Humanized Young Adult Immune system Breast cancer Lymphocytes Tumor-Infiltrating Antigen Antigens CD Internal medicine medicine Tumor Microenvironment Humans Anthracyclines Neoadjuvant therapy Aged CD20 Medicine(all) Tumor microenvironment biology business.industry Carcinoma Ductal Breast FOXP3 Forkhead Transcription Factors Middle Aged Trastuzumab medicine.disease Antigens CD20 Prognosis Neoadjuvant Therapy CD4 Antigens Cancer research biology.protein Female Taxoids Antibody business Research Article |
| Zdroj: | Breast Cancer Research : BCR |
| ISSN: | 1465-542X |
| DOI: | 10.1186/s13058-014-0488-5 |
| Popis: | Introduction Tumor microenvironment immunity is associated with breast cancer outcome. A high lymphocytic infiltration has been associated with response to neoadjuvant chemotherapy, but the contribution to response and prognosis of immune cell subpopulations profiles in both pre-treated and post-treatment residual tumor is still unclear. Methods We analyzed pre- and post-treatment tumor-infiltrating immune cells (CD3, CD4, CD8, CD20, CD68, Foxp3) by immunohistochemistry in a series of 121 breast cancer patients homogeneously treated with neoadjuvant chemotherapy. Immune cell profiles were analyzed and correlated with response and survival. Results We identified three tumor-infiltrating immune cell profiles, which were able to predict pathological complete response (pCR) to neoadjuvant chemotherapy (cluster B: 58%, versus clusters A and C: 7%). A higher infiltration by CD4 lymphocytes was the main factor explaining the occurrence of pCR, and this association was validated in six public genomic datasets. A higher chemotherapy effect on lymphocytic infiltration, including an inversion of CD4/CD8 ratio, was associated with pCR and with better prognosis. Analysis of the immune infiltrate in post-chemotherapy residual tumor identified a profile (cluster Y), mainly characterized by high CD3 and CD68 infiltration, with a worse disease free survival. Conclusions Breast cancer immune cell subpopulation profiles, determined by immunohistochemistry-based computerized analysis, identify groups of patients characterized by high response (in the pre-treatment setting) and poor prognosis (in the post-treatment setting). Further understanding of the mechanisms underlying the distribution of immune cells and their changes after chemotherapy may contribute to the development of new immune-targeted therapies for breast cancer. Electronic supplementary material The online version of this article (doi:10.1186/s13058-014-0488-5) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|